Table 2.
Baseline characteristics stratified by tertiles of platelet-to-lymphocyte ratio
| Tertile 1 (n = 227) | Tertile 2 (n = 227) | Tertile 3 (n = 227) | P-value | r-value | P-value | |
|---|---|---|---|---|---|---|
| Platelet-to-lymphocyte ratio (IQR) | 86.7 (75.1–98.5) | 132.5 (120.0–144.3) | 211.0 (182.0–267.0) | |||
| Platelet count (IQR) | 215 (172–249) | 234 (199–272) | 267 (216–323) | <0.001 | 0.366 | <0.001 |
| Lymphocyte count (IQR) | 2.5 (2.1–3.0) | 1.8 (1.5–2.1) | 1.3 (0.9–1.5) | <0.001 | −0.776 | <0.001 |
| Clinical presentation | ||||||
| Age, years (IQR) | 58 (44–73) | 60 (45–79) | 76 (56–86) | <0.001 | 0.244 | <0.001 |
| Gender (male), n (%) | 129 (56.8) | 107 (47.1) | 93 (41.0) | 0.001 | ||
| Body mass index, kg/m2 (IQR) | 27 (24–31) | 25 (23–28) | 25 (23–28) | <0.001 | −0.220 | <0.001 |
| STEMI, n (%) | 140 (61.7) | 152 (67.3) | 163 (71.8) | 0.022 | ||
| Coronary angiography, n (%) | 192 (84.6) | 169 (74.4) | 161 (70.9) | 0.003 | ||
| Stenting, n (%) | 175 (77.1) | 156 (68.7) | 138 (60.8) | <0.001 | ||
| 1 vessel, n (%) | 146 (64.3) | 124 (54.6) | 111 (48.9) | |||
| 2 vessels, n (%) | 25 (11.0) | 25 (11.0) | 20 (8.8) | |||
| ≥3 vessels, n (%) | 4 (1.7) | 7 (3.0) | 7 (3.1) | |||
| Fibrinolysis, n (%) | 22 (9.7) | 32 (14.2) | 18 (7.9) | 0.542 | ||
| Cardiogenic shock, n (%) | 12 (5.3) | 21 (9.3) | 20 (8.8) | 0.347 | ||
| LVEF ≤40%, n (%) | 47 (20.7) | 48 (21.1) | 76 (33.5) | 0.002 | ||
| Comorbidities | ||||||
| Hypertension, n (%) | 166 (73.5) | 156 (68.7) | 163 (72.1) | 0.755 | ||
| Diabetes mellitus, n (%) | 51 (22.6) | 36 (15.9) | 56 (24.8) | 0.564 | ||
| Hypercholesterolaemia, n (%) | 160 (70.8) | 164 (72.2) | 131 (58.0) | 0.004 | ||
| Renal function failure, n (%) | 12 (5.3) | 15 (6.7) | 25 (11.3) | 0.019 | ||
| Heart failure, n (%) | 9 (4.0) | 9 (4.0) | 14 (6.4) | 0.253 | ||
| Current smoker, n (%) | 149 (66.2) | 123 (54.7) | 88 (38.9) | <0.001 | ||
| Family history of CVD, n (%) | 88 (39.1) | 90 (40.0) | 82 (36.4) | 0.561 | ||
| Laboratory analysis | ||||||
| Total Leucocytes, G/L (IQR) | 10.5 (7.8–12.6) | 9.5 (7.5–12.5) | 9.6 (7.4–11.7) | 0.170 | −0.088 | 0.022 |
| C-reactive protein, mg/dL (IQR) | 0.69 (0.28–1.39) | 0.62 (0.40–1.29) | 0.82 (0.43–3.2) | 0.006 | 0.233 | <0.001 |
| Troponin T (max), µg/L (IQR) | 2.0 (0.7–4.6) | 2.5 (1.1–5.1) | 1.6 (0.5–4.4) | 0.029 | −0.044 | 0.257 |
| Creatin kinase (max), U/L (IQR) | 732 (317–1649) | 939 (404–1929) | 454 (204–1516) | 0.001 | −0.095 | 0.013 |
| LDH (max), U/L (IQR) | 422 (273–617) | 472 (306–704) | 404 (282–624) | 0.089 | −0.016 | 0.684 |
| Gamma-GT, µkat/L (IQR) | 31 (20–55) | 26 (17–42) | 29 (20–50) | 0.010 | −0.047 | 0.219 |
| Butyrylcholinesterase, U/L (IQR) | 7.3 (6.0–8.6) | 6.9 (5.7–8.5) | 6.3 (5.4–7.7) | <0.001 | −0.179 | <0.001 |
| Total bilirubin, µmol/L (IQR) | 0.55 (0.39–0.81) | 0.52 (0.38–0.77) | 0.59 (0.40–0.85) | 0.124 | 0.034 | 0.379 |
| Creatinine, mg/dL (IQR) | 1.0 (0.8–1.2) | 1.0 (0.8–1.2) | 1.0 (0.8–1.2) | 0.239 | 0.052 | 0.176 |
| NT-proBNP, pg/mL(IQR) | 840 (295–2710) | 1427 (431–3832) | 2239 (716–7788) | 0.001 | 0.233 | <0.001 |
| Cardiovascular mortality | 54 (23.8) | 59 (26.0) | 87 (38.3) | 0.001 |
Categorical data are presented as counts and percentages and analysed using χ2 test. Continuous data are presented as median and the respective interquartile range and analysed using Mann–Whitney U test. Correlation refers Spearman Rho correlation coefficient.
CVD, coronary vessel disease; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; STEMI, ST-elevation myocardial infarction.
Significance of bold values is indicated by a p-value of <0.05.